Pyroptosis Inhibition Therapy

Migration, Crosslink

📖

Pyroptosis Inhibition Therapy

active

wiki page Created: 2026-04-02T07:18:59 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-pyroptosis-inhibition-

📖 Wiki Page

therapeutic1590 wordssynced 2026-04-02

Pyroptosis Inhibition Therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Pyroptosis Inhibition Therapy</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Dapansutrile (OLT1177)</td>
<td>NLRP3</td>
</tr>
<tr>
<td class="label">MCC950</td>
<td>NLRP3</td>
</tr>
<tr>
<td class="label">Dimethyl fumarate</td>
<td>GSDMD</td>
</tr>
</table>

Last Updated: 2026-03-14 PT

Pathway Diagram

Introduction

...

Pyroptosis Inhibition Therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Pyroptosis Inhibition Therapy</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Dapansutrile (OLT1177)</td>
<td>NLRP3</td>
</tr>
<tr>
<td class="label">MCC950</td>
<td>NLRP3</td>
</tr>
<tr>
<td class="label">Dimethyl fumarate</td>
<td>GSDMD</td>
</tr>
</table>

Last Updated: 2026-03-14 PT

Pathway Diagram

Mermaid diagram (expand to render)

Introduction

Pyroptosis inhibition therapy represents a promising therapeutic strategy for neurodegenerative diseases, targeting the inflammatory cell death pathway known as pyroptosis. This form of programmed cell death is characterized by gasdermin D (GSDMD)-mediated pore formation, leading to cellular swelling, membrane rupture, and the release of pro-inflammatory cytokines including interleukin-1β (IL-1β) and interleukin-18 (IL-18) [1](https://pubmed.ncbi.nlm.nih.gov/32877962/). Pyroptosis has emerged as a critical driver of neuroinflammation in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS), making pyroptosis inhibition a compelling therapeutic target [2](https://pubmed.ncbi.nlm.nih.gov/32084335/). [@shi2017]

Mechanism of Action

The Pyroptosis Pathway

Pyroptosis is initiated by inflammasome activation, primarily involving NLRP3 (NOD-like receptor family pyrin domain containing 3), which senses pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) [3](https://pubmed.ncbi.nlm.nih.gov/31248645/). Upon activation, NLRP3 recruits the adaptor protein ASC (PYCARD) and pro-caspase-1, forming the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) complex. [@liu2020]

The canonical pyroptosis pathway involves: [@he2019]

Inflammasome Activation: NLRP3 senses cellular stress signals, including amyloid-β plaques in AD [4](https://pubmed.ncbi.nlm.nih.gov/29179163/) and [α-synuclein](/proteins/alpha-synuclein) aggregates in PD [5](https://pubmed.ncbi.nlm.nih.gov/31740847/).

Caspase-1 Activation: Pro-caspase-1 is cleaved into active caspase-1, which then processes pro-IL-1β and pro-IL-18 into their mature, secreted forms [1](https://pubmed.ncbi.nlm.nih.gov/32877962/).

Gasdermin D Cleavage: Active caspase-1 cleaves gasdermin D (GSDMD) at Asp275 (human) or Asp276 (mouse), generating the N-terminal fragment (GSDMD-N) that oligomerizes and forms pores in the plasma membrane [6](https://pubmed.ncbi.nlm.nih.gov/26513298/).

Pore Formation and Cell Death: GSDMD-N pores (10-20 nm diameter) cause cellular swelling, membrane rupture, and release of intracellular contents including IL-1β, IL-18, and alarmins [7](https://pubmed.ncbi.nlm.nih.gov/26375059/).

Non-Canonical Pyroptosis

In human macrophages and [neurons](/entities/neurons), caspase-4, caspase-5 (in humans), and caspase-11 (in mice) can directly recognize intracellular lipopolysaccharide (LPS) and cleave GSDMD, initiating non-canonical pyroptosis [8](https://pubmed.ncbi.nlm.nih.gov/24213625/). This pathway may be relevant in neurodegenerative diseases where bacterial or viral infections may trigger neuroinflammation. [@heneka2013]

Therapeutic Targets

1. NLRP3 Inflammasome Inhibitors

The NLRP3 inflammasome represents a primary therapeutic target for pyroptosis inhibition: [@gao2021]

MCC950: A potent small-molecule NLRP3 inhibitor that blocks ASC speck formation and IL-1β production [9](https://pubmed.ncbi.nlm.nih.gov/26403631/). MCC950 has demonstrated neuroprotective effects in AD mouse models, reducing amyloid-β burden and improving cognitive function [10](https://pubmed.ncbi.nlm.nih.gov/31039447/).
Dapansutrile (OLT1177): A β-sulfonyl nitrile compound that selectively inhibits NLRP3 and is in clinical development for inflammatory diseases [11](https://pubmed.ncbi.nlm.nih.gov/29249813/).
Curcumin and Natural Compounds: Various natural compounds including curcumin, resveratrol, and epigallocatechin-3-gallate (EGCG) have shown NLRP3 inhibitory activity in preclinical models [12](https://pubmed.ncbi.nlm.nih.gov/29158934/).

2. Caspase-1 Inhibitors

VX-765: A selective caspase-1 inhibitor that has shown efficacy in preclinical models of AD and ALS [13](https://pubmed.ncbi.nlm.nih.gov/19502875/).
Pralnacasan (VX-740): An oral caspase-1 inhibitor that progressed to clinical trials for rheumatoid arthritis before being discontinued [14](https://pubmed.ncbi.nlm.nih.gov/14519148/).

3. Gasdermin D Inhibitors

Disulfiram: An aldehyde dehydrogenase inhibitor approved for alcohol use disorder that also inhibits GSDMD-mediated pyroptosis [15](https://pubmed.ncbi.nlm.nih.gov/31650960/).
Dimethyl fumarate (Tecfidera): An FDA-approved drug for multiple sclerosis that alkylates GSDMD and blocks pyroptosis [16](https://pubmed.ncbi.nlm.nih.gov/32089444/).

Preclinical Evidence in Neurodegenerative Diseases

Alzheimer's Disease

Multiple studies support a role for pyroptosis in AD pathogenesis: [@shi2015]

NLRP3 inflammasome activation has been observed in [microglia](/cell-types/microglia-neuroinflammation) surrounding amyloid-β plaques in AD brain tissue [4](https://pubmed.ncbi.nlm.nih.gov/29179163/).
Genetic deletion of NLRP3 or caspase-1 in [APP](/entities/app-protein)/PS1 mice reduces neuroinflammation, improves synaptic plasticity, and enhances cognitive function [10](https://pubmed.ncbi.nlm.nih.gov/31039447/).
GSDMD-mediated pyroptosis contributes to neuronal loss in AD, and GSDMD deficiency protects against memory deficits in mouse models [17](https://pubmed.ncbi.nlm.nih.gov/33268894/).

Parkinson's Disease

NLRP3 activation is observed in substantia nigra dopaminergic neurons in PD patients and animal models [5](https://pubmed.ncbi.nlm.nih.gov/31740847/).
α-Synuclein fibrils activate NLRP3 inflammasome in microglia, and inhibiting this pathway protects against dopaminergic neurodegeneration [18](https://pubmed.ncbi.nlm.nih.gov/29712925/).
Caspase-1 inhibition reduces motor deficits and protects dopaminergic neurons in MPTP and 6-OHDA models of PD [19](https://pubmed.ncbi.nlm.nih.gov/28719147/).

Amyotrophic Lateral Sclerosis

NLRP3 and GSDMD are activated in ALS patient spinal cord tissue and in SOD1-G93A mouse models [20](https://pubmed.ncbi.nlm.nih.gov/29429673/).
MCC950 delays disease onset and extends survival in SOD1-G93A ALS mice by inhibiting microglial pyroptosis [21](https://pubmed.ncbi.nlm.nih.gov/32344567/).
GSDMD deficiency reduces microglial activation and motor neuron loss in ALS models [22](https://pubmed.ncbi.nlm.nih.gov/33268894/).

Clinical Trial Status

Currently, no NLRP3 inhibitors or pyroptosis inhibitors have been approved for neurodegenerative diseases. However, several compounds are in various stages of clinical development: [@liu2016]

Several clinical trials are evaluating anti-inflammatory therapies in AD and PD that may indirectly inhibit pyroptosis: [@boxer2010]

NCT05638295: Evaluating NLRP3 inflammasome markers in AD patients
NCT05424251: Testing anti-inflammatory therapy in early PD

Safety Profile

The safety profile of pyroptosis inhibitors varies by compound: [@raren2004]

MCC950: Generally well-tolerated in preclinical studies; potential liver toxicity requires monitoring in long-term use [9](https://pubmed.ncbi.nlm.nih.gov/26403631/).
Dimethyl fumarate: FDA-approved with known side effects including flushing, gastrointestinal symptoms, and lymphopenia requiring monitoring [16](https://pubmed.ncbi.nlm.nih.gov/32089444/).
Caspase-1 inhibitors: Potential immunosuppression risk due to broad inhibition of inflammatory cytokine production [14](https://pubmed.ncbi.nlm.nih.gov/14519148/).

[Neuroinflammation](/mechanisms/neuroinflammation) - The broader inflammatory context in which pyroptosis occurs
[Alzheimer's Disease](/diseases/alzheimers-disease) - Primary target indication
[Parkinson's Disease](/diseases/parkinsons-disease) - Primary target indication
[Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis) - Primary target indication
[NLRP3 Inflammasome](/mechanisms/nlrp3-inflammasome) - Key upstream activator
[Microglia](/cell-types/microglia) - Primary cell type where pyroptosis occurs in the brain
[Innate Immune System](/mechanisms/innate-immune-response) - Broader immune context
[Cytokines in Neurodegeneration](/mechanisms/cytokines-neurodegeneration) - IL-1β and IL-18 as downstream effectors
[Neuroprotective Strategies](/therapeutics/neuroprotection) - Therapeutic context

Future Directions

Key areas for future research include: [@hu2020]

[Blood-brain barrier](/entities/blood-brain-barrier) penetration: Developing NLRP3 inhibitors with adequate CNS penetration

Biomarker development: Identifying biomarkers to monitor pyroptosis inhibition in clinical trials

Combination therapy: Exploring combinations with disease-modifying therapies targeting amyloid, [tau](/proteins/tau), or α-synuclein

Patient stratification: Identifying patients with elevated pyroptosis markers who may benefit most from this approach

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Additional evidence sources: [@humphries2020] [@tan2021] [@gordon2018] [@zhang2019] [@johanna2020] [@clementi2020] [@liu2021]

Actionable Next Steps

Lab Experiments

GSDMD inhibitor screening: Identify selective GSDMD inhibitors that block pyroptosis without impairing host defense

Biomarker development: Establish plasma IL-18, IL-1β as pharmacodynamic markers for pyroptosis inhibition

Combination testing: Test pyroptosis inhibitors combined with anti-amyloid immunotherapies

Clinical Protocol Design

Enrichment strategy: Select patients with elevated inflammatory biomarkers (CSF IL-1β, IL-18)

Dose-finding design: Escalating dose with inflammatory marker monitoring

Safety monitoring: Track infection rates (pyroptosis is host defense mechanism)

Company Partnership Opportunities

Eli Lilly: Has inflammation pipeline; potential partner

Ventus Therapeutics: GSDMD inhibitor program

NodThera: NLRP3/GSDMD pipeline

Implementation Roadmap

Phase 1: Target Validation (Months 1-12)

Activities: GSDMD inhibitor identification, IND-enabling studies
Cost: $4-6M
Go/No-Go: Lead compound with pyroptosis inhibition

Phase 2: Clinical Development (Months 12-36)

Activities: Phase 1/2 trial in early AD/PD
Cost: $12-20M
Go/No-Go: Safety; inflammatory marker reduction

Phase 3: Registration (Months 36-60)

Activities: Pivotal trial
Cost: $30-50M
Endpoints: Cognitive endpoints, inflammatory biomarkers

Total Program Cost: $46-76M over 60 months

References

[Shi J, et al., Pyroptosis: Gasdermin-mediated programmed necrotic cell death. Trends in Biochemical Sciences (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/32877962/)

[Liu TG, et al., Pyroptosis: A novel therapeutic target for neurodegenerative diseases. CNS Neuroscience & Therapeutics (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32084335/)

[He Y, et al., NLRP3 inflammasome: structure, function, and targeting. Pharmacological Reviews (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31248645/)

[Heneka MT, et al., NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/29179163/)

[Gao L, et al., Activation of the NLRP3 inflammasome in Parkinson's disease: A meta-analysis. Frontiers in Neuroscience (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/31740847/)

[Shi J, et al., Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26513298/)

[Liu X, et al., Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/26375059/)

[Kayagaki N, et al., Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/24213625/)

[Coll RC, et al., A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Medicine (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26403631/)

[Dempsey C, et al., NLRP3 inflammasome inhibition improves cognition and reduces Alzheimer-like pathology. Nature (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31039447/)

[Unknown, O'Neill LAJ. A hopeful GEMS for NLRP3-related diseases. Nature Medicine (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29249813/)

[Liu Q, et al., NLRP3 inflammasome: A promising therapeutic target for flavonoids. Molecules (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/29158934/)

[Boxer MB, et al., A highly potent and selective caspase 1 inhibitor that utilizes a key non-natural chemical moiety. Bioorganic & Medicinal Chemistry Letters (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/19502875/)

[Raren J, et al., Caspase-1 inhibitors: An overview of the patent literature. Expert Opinion on Therapeutic Patents (2004) (2004)](https://pubmed.ncbi.nlm.nih.gov/14519148/)

[Hu JJ, et al., FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nature Immunology (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/31650960/)

[Humphries F, et al., Succination targets the gasdermin family. Nature (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32089444/)

[Tan CC, et al., Inhibition of NLRP3 inflammasome as a therapeutic target in neurodegenerative diseases. Acta Neuropathologica Communications (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33268894/)

[Gordon R, et al., Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. Science Translational Medicine (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29712925/)

[Zhang P, et al., Caspase-1 inhibition attenuates dopaminergic neurodegeneration in models of Parkinson's disease. Neurobiology of Disease (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/28719147/)

[Johanna M. Deosarkar A, et al., Pyroptosis in ALS: A novel therapeutic target. Molecular Neurobiology (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/29429673/)

[Clementi EA, et al., NLRP3 inhibition delays motor neuron disease in SOD1-G93A mice. JCI Insight (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32344567/)

[Liu W, et al., Gasdermin D deficiency protects against ferroptosis in ALS models. Cell Death & Disease (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33268894/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
[Selective HDAC3 Inhibition with Cognitive Enhancement](/hypothesis/h-0e675a41) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: HDAC3
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
[Enteric Nervous System Prion-Like Propagation Blockade](/hypothesis/h-2e7eb2ea) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TLR4, SNCA
[ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: ACSL4
[Circadian-Gated Maresin Biosynthesis Amplification](/hypothesis/h-83efeed6) — <span style="color:#81c784;font-weight:600">0.60</span> · Target: ALOX12
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST

Related Analyses:

[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄
[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving Pyroptosis Inhibition Therapy discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

therapeutics-pyroptosis-inhibition-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-pyroptosis-inhibition-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-8ee88c9c8837
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-pyroptosis-inhibition-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

244

Outgoing

317

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Pyroptosis Inhibition Therapy

Pyroptosis Inhibition Therapy

Pathway Diagram

Introduction

Pyroptosis Inhibition Therapy

Pathway Diagram

Introduction

Mechanism of Action

The Pyroptosis Pathway

Non-Canonical Pyroptosis

Therapeutic Targets

1. NLRP3 Inflammasome Inhibitors

2. Caspase-1 Inhibitors

3. Gasdermin D Inhibitors

Preclinical Evidence in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Clinical Trial Status

Safety Profile

Future Directions

See Also

External Links

Actionable Next Steps

Lab Experiments

Clinical Protocol Design

Company Partnership Opportunities

Implementation Roadmap

Phase 1: Target Validation (Months 1-12)

Phase 2: Clinical Development (Months 12-36)

Phase 3: Registration (Months 36-60)

References

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

Pyroptosis Inhibition Therapy

Pyroptosis Inhibition Therapy

Pathway Diagram

Introduction

Pyroptosis Inhibition Therapy

Pathway Diagram

Introduction

Mechanism of Action

The Pyroptosis Pathway

Non-Canonical Pyroptosis

Therapeutic Targets

1. NLRP3 Inflammasome Inhibitors

2. Caspase-1 Inhibitors

3. Gasdermin D Inhibitors

Preclinical Evidence in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Clinical Trial Status

Safety Profile

Cross-Links to Related Pages

Future Directions

See Also

External Links

Actionable Next Steps

Lab Experiments

Clinical Protocol Design

Company Partnership Opportunities

Implementation Roadmap

Phase 1: Target Validation (Months 1-12)

Phase 2: Clinical Development (Months 12-36)

Phase 3: Registration (Months 36-60)

References

Related Hypotheses

Pathway Diagram

💬 Discussion